Chemistry:Hemantane
Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed.[1] It was developed and studied in Russia.[1]
It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, as a selective MAO-B inhibitor, and as showing various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum.[1][2] The drug has also been theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects.[1] Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation.[1]
The drug was first described by 2000.[3][4]
The dosage of gimantan is standardized to 50mg tablet strength.[5]
Chemistry
Gimantan is synthesized, according to the Leuckart reaction, by heating adamantanone and azepane in the presence of formic acid.[6][7][8]
See also
- Bromantane
- Gludantan
- List of Russian drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal 5 (2): 83–91. 2011. doi:10.1134/S1819712411010028. ISSN 1819-7124.
- ↑ "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Frontiers in Pharmacology 13. 2022. doi:10.3389/fphar.2022.927703. PMID 36263121.
- ↑ "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]" (in Russian). Eksperimental'naia i Klinicheskaia Farmakologiia 63 (5): 3–6. 2000. PMID 11109514.
- ↑ "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]" (in Russian). Eksperimental'naia i Klinicheskaia Farmakologiia 64 (6): 13–16. 2001. PMID 11871228.
- ↑ "Gimantan Tablets: Analysis and Standardization.". Pharmaceutical Chemistry Journal 36 (1): 48–50. January 2002. doi:10.1023/A:1015761110991.
- ↑ "Pharmaceutical analysis and standardization of gimantan parenteral dosage form.". Pharmaceutical Chemistry Journal 45 (8): 499–502. November 2011. doi:10.1007/s11094-011-0664-1.
- ↑ "SU1825499 "N-(2-adamantyl)hexamethyleneimine hydrochloride with anticataleptic activity" (in Russian). Byull. Izobret. 4. 2010.
- ↑ "Analysis and Standardization of the New Domestic Antiparkinsonian Drug Gimantan". Pharmaceutical Chemistry Journal 35 (11): 635–638. November 2001. doi:10.1023/A:1015158213734.
 |  |
